To eat or not to eat: A role for ghrelin and LEAP2 in eating disorders?

Neuroscience Applied Pub Date : 2024-01-01 DOI:10.1016/j.nsa.2024.104045

Virginie Tolle , Chloe Tezenas du Montcel , Julia Mattioni , Erik Schéle , Odile Viltart , Suzanne L. Dickson

{"title":"To eat or not to eat: A role for ghrelin and LEAP2 in eating disorders?","authors":"Virginie Tolle , Chloe Tezenas du Montcel , Julia Mattioni , Erik Schéle , Odile Viltart , Suzanne L. Dickson","doi":"10.1016/j.nsa.2024.104045","DOIUrl":null,"url":null,"abstract":"<div><p>Ghrelin is an orexigenic hormone that orchestrates many diverse behaviours of relevance for feeding control. It appears to operate as a hunger hormone, organizing food intake into meals and ensuring that we seek out and consume a variety of foods. With this physiological biography, the ghrelin system, including the pathways through which it operates, has been interrogated for its role in the aetiology, pathology and treatment of eating disorders. While common obesity does not appear to be a hyperghrelinemic state, it would be difficult to completely rule out enhanced ghrelin signalling. At the other end of the body weight spectrum, it can be questioned whether patients suffering from anorexia nervosa develop ghrelin resistance and/or have high levels of LEAP2, an endogenous antagonist for GHSR, since they do not eat despite having high ghrelin levels. The purpose of this review is to outline gaps in knowledge in the ghrelin field, including in the context of eating disorders.</p></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"3 ","pages":"Article 104045"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772408524001108/pdfft?md5=8ad982899b5a5fafe8d181bedbd2405a&pid=1-s2.0-S2772408524001108-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Applied","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772408524001108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Ghrelin is an orexigenic hormone that orchestrates many diverse behaviours of relevance for feeding control. It appears to operate as a hunger hormone, organizing food intake into meals and ensuring that we seek out and consume a variety of foods. With this physiological biography, the ghrelin system, including the pathways through which it operates, has been interrogated for its role in the aetiology, pathology and treatment of eating disorders. While common obesity does not appear to be a hyperghrelinemic state, it would be difficult to completely rule out enhanced ghrelin signalling. At the other end of the body weight spectrum, it can be questioned whether patients suffering from anorexia nervosa develop ghrelin resistance and/or have high levels of LEAP2, an endogenous antagonist for GHSR, since they do not eat despite having high ghrelin levels. The purpose of this review is to outline gaps in knowledge in the ghrelin field, including in the context of eating disorders.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

吃还是不吃？胃泌素和 LEAP2 在进食障碍中的作用？

胃泌素是一种促食欲激素，能协调许多与进食控制有关的不同行为。它似乎是一种饥饿荷尔蒙，能将食物摄入组织成餐，并确保我们寻找和摄入各种食物。有了这一生理传记，人们开始研究胃泌素系统，包括其运作途径，以了解它在饮食失调的病因、病理和治疗中的作用。虽然普通肥胖症似乎并不属于高胃泌素血症，但很难完全排除胃泌素信号增强的可能性。在体重谱的另一端，神经性厌食症患者是否会产生胃泌素抵抗和/或具有高水平的内源性胃泌素拮抗剂 LEAP2（一种 GHSR 的内源性拮抗剂），这一点值得商榷，因为尽管他们的胃泌素水平很高，但他们并不进食。本综述旨在概述胃泌素领域的知识空白，包括饮食失调方面的知识空白。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuroscience Applied

自引率

0.00%

发文量